As of June 30, 2026, Celon Pharma SA carries a market capitalization of 251.23M, placing it among publicly traded companies globally. Its enterprise value stands at 273.13M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 251.23M |
| Enterprise Value | 273.13M |
Celon Pharma SA's next confirmed earnings release is scheduled for November 18, 2026.
| Earnings Date | 11/18/2026 |
As of June 30, 2026, Celon Pharma SA has 53.91M shares outstanding.
| Shares Outstanding | 53.91M |
As of June 30, 2026, Celon Pharma SA trades at a trailing price-to-earnings ratio of 9.43.
| PE Ratio | 9.43 |
| PB Ratio | 2.16 |
| P/TBV Ratio | 2.28 |
| P/FCF Ratio | -34.63 |
| P/OCF Ratio | 38.27 |
As of June 30, 2026, Celon Pharma SA trades at an EV/EBITDA multiple of 42.78 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. These enterprise value multiples are built on an enterprise value of 273.13M versus a market cap of 251.23M, with the gap driven by net debt and cash on the balance sheet.
| EV / EBITDA | 42.78 |
As of June 30, 2026, Celon Pharma SA maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.76, indicating elevated leverage, while an interest coverage ratio of 7.55 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.37 |
| Quick Ratio | 0.38 |
| Debt / Equity | 25.76 |
| Debt / EBITDA | 4.68 |
| Interest Coverage | 7.55 |
Over the twelve months ended June 30, 2026, Celon Pharma SA posted a return on equity (ROE) of 25.07, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 18.22, measuring how efficiently the asset base is converted into earnings.
| Return on Equity (ROE) | 25.07 |
| Return on Assets (ROA) | 18.22 |
| Employee Count | 561.00 |
Over the twelve months ended June 30, 2026, Celon Pharma SA recorded 3.38M in income tax expense.
| Income Tax | 3.38M |
As of the close on November 17, 2026, Celon Pharma SA's stock has declined approximately 26.49% over the past 52 weeks. The 50-day moving average sits at 4.33, while the 200-day moving average is 4.76.
| 52-Week Price Change | -26.49% |
| 50-Day Moving Average | 4.33 |
| 200-Day Moving Average | 4.76 |
These figures cover the twelve months ended June 30, 2026. EBITDA reached 6.38M, while operating income came in at -2.44M.
| Operating Income | -2.44M |
| Net Income | 25.78M |
| EBITDA | 6.38M |
| EBIT | -1.13M |
| Earnings Per Share (EPS) | 0.49 |
As of June 30, 2026, Celon Pharma SA holds 8.00M in cash and equivalents against 29.90M in total debt, resulting in a net debt position of 11.37M. Total book value stands at 116.05M, with working capital of 7.86M providing operational flexibility.
| Cash & Cash Equivalents | 8.00M |
| Total Debt | 29.90M |
| Net Debt | 11.37M |
| Equity (Book Value) | 116.05M |
| Book Value Per Share | 2.15 |
| Working Capital | 7.86M |
Celon Pharma SA produced 6.35M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -13.37M in capital expenditures, free cash flow totaled -7.02M - equivalent to -0.13 per share.
| Operating Cash Flow | 6.35M |
| Capital Expenditures | -13.37M |
| Free Cash Flow | -7.02M |
| FCF Per Share | -0.13 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.89: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.21, meaning Celon Pharma SA raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -6.21 |
| FCF Yield | -2.89 |
Already premium?